Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
From Share _ talk (Zak)
Although there would appear to have been more stages to FDA approval for #HEMO than there are to Nirvana, it does look as though the company is heading for clinical stage heaven
@HemogenyxPharma
The company spent months preparing the IP APPLICATION FOR CBR to ensure they had covered all potential diseases and viruses it could cure.
IF CBR WORKS they will not leave this IP situation until the last minute.
So that brings this timeline forward till late july august at the latest.
Am I not correct in saying if CBR had failed say IN Vivo the company would be obliged to RNS
this.
JHFH.
HULVER posted 12 may
Remember that there has also been, and is, a clock ticking on CBR too.
They only have until approx September this year before the patent becomes available to all and others can see what Hemo has been experimenting with - so I think particular scientists will have had to have been flat out on that too (whilst investors here have been focused on CAR-T and IND).
I assume the sept date correct as no one has corrected him.
SO we now have 2 timelines one 6 june one for CBR sep.
The clock is ticking both very close.
If the IND has not been submitted yet are we trying to align this with the grant, stated to be announced 11 april.
W hat are the fast track benefits of being awarded the grant , if we have applied and in which casse are successful.
Broker
@optivalondon
. For IPO's and secondary placements, contact: sam.sehmbi@optivasecurities.com
Sam
@sam_sehmbi
·
1h
It was great to meet
@vmsandler
in person at our headquarters. A lot of work to do whilst waiting for an update from the FDA, but excited to see what 2023 brings with potential clinical trials on the horizon for CAR-T. #HEMO #hemogenyx #pharmaceuticals #stockexchange